UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

The New England journal of medicine, 2019-05, Vol.380 (22), p.2104-2115

2019

Link zum Volltext

Verfügbarkeit prüfen

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

The New England journal of medicine, 2019-08, Vol.381 (8), p.727-738

2019

Link zum Volltext

Verfügbarkeit prüfen

How I treat frontline transplantation-eligible multiple myeloma

Blood, 2022-05, Vol.139 (19), p.2882-2888

Perrot, Aurore

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Blood cancer journal (New York), 2021-05, Vol.11 (5), p.89-5, Article 89

2021

Link zum Volltext

Verfügbarkeit prüfen

Multiple Myeloma: Heterogeneous in Every Way

Cancers, 2021-03, Vol.13 (6), p.1285

2021

Link zum Volltext

Verfügbarkeit prüfen

Risk and Response-Adapted Treatment in Multiple Myeloma

Cancers, 2020-11, Vol.12 (12), p.3497

2020

Link zum Volltext

Verfügbarkeit prüfen

Management of a Young Patient With High-risk Multiple Myeloma Complicated by Acquired von Willebrand Syndrome: A Diagnostic and Therapeutic Emergency

Plasmatology, 2024-01, Vol.18

2024

Link zum Volltext

Verfügbarkeit prüfen

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry

Blood cancer journal (New York), 2023-02, Vol.13 (1), p.30-30, Article 30

2023

Link zum Volltext

Verfügbarkeit prüfen

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions

Blood cancer journal (New York), 2023-10, Vol.13 (1), p.160-160, Article 160

2023

Link zum Volltext

Verfügbarkeit prüfen

Revised international staging system allocation in the ICARIA‐MM study: Practical challenges and impact on outcome

EJHaem, 2022-02, Vol.3 (1), p.168-170

2022

Link zum Volltext

Verfügbarkeit prüfen

Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database

Vaccines (Basel), 2020-12, Vol.8 (4), p.722

2020

Link zum Volltext

Verfügbarkeit prüfen

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA‐HIGH‐RISK CYTOGENETICS: ICARIA‐MM AND IKEMA SUBGROUP ANALYSIS

HemaSphere, 2023-08, Vol.7 (S3), p.e27700c7-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)

Clinical hematology international, 2023-03, Vol.5 (1), p.38-42

2023

Link zum Volltext

Verfügbarkeit prüfen

When dystrophic plasma cells do not recognize themselves in the mirror

EJHaem, 2020-11, Vol.1 (2), p.408-408

2020

Link zum Volltext

Verfügbarkeit prüfen

P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA‐MM AND IKEMA STUDIES

HemaSphere, 2023-08, Vol.7 (S3), p.e3398301-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Lactic acidosis and hypoglycemia as markers of disease progression of multiple myeloma: A case report

EJHaem, 2021-08, Vol.2 (3), p.539-544

2021

Link zum Volltext

Verfügbarkeit prüfen

P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC‐2 STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e162590e-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Bispecific antibodies in myeloma

Hématologie, 2021-06, Vol.27 (S3), p.19-25

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 236

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(232)
Mit Volltextzugriff
(231)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(92)
Life Sciences & Biomedicine
(90)
Humans
(69)
Hematology
(68)
Life Sciences
(48)
Multiple Myeloma
(41)
Oncology
(36)
Female
(32)
Middle Aged
(30)
Aged
(29)
Male
(28)
Cancer
(25)
Multiple Myeloma - Drug Therapy
(25)
Adult
(18)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(18)
Prognosis
(18)
Dexamethasone
(17)
Patients
(17)
Monoclonal Antibodies
(15)
Medicin Och Hälsovetenskap
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(85)
Clinical Lymphoma, Myeloma And Leukemia
(35)
Journal Of Clinical Oncology
(18)
British Journal Of Haematology
(13)
Haematologica
(12)
Hemasphere
(6)
Leukemia
(6)
Ejhaem
(4)
Leukemia & Lymphoma
(4)
Advances In Therapy
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

How I treat frontline transplantation-eligible multiple myeloma

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Multiple Myeloma: Heterogeneous in Every Way

Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods

Risk and Response-Adapted Treatment in Multiple Myeloma

Management of a Young Patient With High-risk Multiple Myeloma Complicated by Acquired von Willebrand Syndrome: A Diagnostic and Therapeutic Emergency

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions

Revised international staging system allocation in the ICARIA‐MM study: Practical challenges and impact on outcome

Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA‐HIGH‐RISK CYTOGENETICS: ICARIA‐MM AND IKEMA SUBGROUP ANALYSIS

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)

When dystrophic plasma cells do not recognize themselves in the mirror

P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA‐MM AND IKEMA STUDIES

Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study

Lactic acidosis and hypoglycemia as markers of disease progression of multiple myeloma: A case report

P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC‐2 STUDY

P904: LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL‐LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA– FINAL ANALYSIS AT 2‐YEAR FOLLOW‐UP

P979: PATIENT‐REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL‐WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL‐WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

Bispecific antibodies in myeloma

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Suchergebnisse filtern